Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "【Order On Telegram: @Chem2Door】Where To Buy Eszopiclone (Lunesta) In San Francisco,.cde2"

Looking for quality documents?
external link icon
Repligen Corporation to Present at Upcoming May Investor Conferences
WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences.
RBC Capital Markets’ 2024 Global Healthcare Conference, being held in New York on May 14-15. Jason K. Garland, Chief Financial Officer, is scheduled to participate in an analyst-led discussion on May 14, 2024 at 10:30 a.m. ET, in addition to a series of one-on-one meetings with investors. Craig-Hallum’s 21 st Annual Institutional Investor Conference, being held in Minneapolis on May 29. Jason K. Garland, Chief Financial officer will participate in a series of one-on-one meetings with investors. Leerink Partners’ 2024 Healthcare Crossroads Conference, being held in Austin, Texas on May 28-29. Jason K. Garland, Chief Financial Officer, is scheduled to participate in an analyst-led discussion on May 30, 2024 at 8:40 a.m. CT, in addition to a
external link icon
Repligen Appoints Maggie A. Pax to Board of Directors
WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax. This appointment expands the size of Repligen’s board from eight to nine members. Ms. Pax brings to Repligen over 25 years of experience leading the development and execution of growth strategies for global companies. This includes eight years with Thermo Fisher Scientific, where, from 2016–2020, she served as Vice President, Strategy and Innovation for the clinical supply chain business. In this role, she led strategic planning, developed customer-facing innovation programs, and drove the business case for the company’s multi-billion acquisition of Patheon, a leading biopharmaceutical contract manufacturer. Karen A. Dawes, Chairperson of the Board of Directors for Repligen, said, “We’re very happy to welcome Maggie Pax as a terrific addition to the Repligen Board with extensive experience in
external link icon
Repligen Announces Agreement to Acquire Fluid Management Innovator Metenova
Proposed acquisition adds market leading magnetic mixing technology for upstream and downstream bioprocess applications Expands Repligen’s Fluid Management portfolio, complements single-use bag offering WALTHAM, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held Metenova AB (Metenova) of Mölndal, Sweden. Metenova is projected to generate revenues of $24 million to $25 million for fiscal year 2023, led by the success of its magnetic mixing and drive train technologies that are widely used by global biopharmaceutical companies and contract development and manufacturing organizations (CDMOs). The company recently entered the single-use mixing market with the launch of its MixOne platform, leveraging the success of its existing stainless steel (repeat-use) product line.
external link icon
Repligen Corporation to Present at Wells Fargo Healthcare Conference
WALTHAM, Mass., Sept. 01, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at the Wells Fargo Healthcare Conference being held September 6 -8 in Boston. Tony J. Hunt, President and Chief Executive Officer, will participate in an analyst-led discussion on Friday, September 8, at 10:15 a.m. ET. A live webcast of the conference presentation will be accessible through Repligen’s  Investor Relations website at www.repligen.com , and will be available for replay for a limited period of time following the event. About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical
external link icon
Repligen Appoints Martin D. Madaus to Board of Directors
WALTHAM, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences tools industry leader Martin D. Madaus. Dr. Madaus brings to the Repligen board over 25 years of industry experience, including five years as Chairman, President and Chief Executive Officer of Millipore Corporation, where he was integral to the company’s transformation into a life science leader, and its acquisition by Merck KGaA in 2010. He is an active board leader, currently serving two public companies; as Lead Director for precision health technology company Quanterix Corporation and as Board member for mass cytometry player Standard BioTools, Inc. (previously Fluidigm Corporation).  Karen A. Dawes, Chairperson of the Board of Directors for Repligen, said, “We are thrilled to welcome Dr. Madaus to the Repligen board, as the company continues to drive innovation in bioprocessing and expand into new markets. Martin’s
external link icon
Repligen Appoints Dr. Konstantin Konstantinov to Board of Directors
WALTHAM, Mass., May 26, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of Konstantin Konstantinov, Ph.D., a life sciences and bioprocessing industry expert. Dr. Konstantinov brings to the director role nearly 30 years of relevant experience, including his current position as Chief Technology Officer at Codiak BioSciences, where he previously served for six years as Executive Vice President, Manufacturing & Process Sciences.
Dr. Konstantinov has been directly involved in the development and commercialization of multiple biotherapeutic modalities, including monoclonal antibodies, blood factors, gene therapy vectors and exosomes. Over the past decade he has pioneered the development of integrated continuous biomanufacturing, which is becoming a strategic technological trend in the bioprocessing industry. “We are delighted to welcome Dr. Konstantinov to our board,” said Karen A. Dawes, Chairperson of the Board
external link icon
Repligen Corporation to Present at Barclays Global Healthcare Conference
WALTHAM, Mass., March 03, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the Barclays Global Healthcare Conference being held March 9-11. Jon Snodgres, Chief Financial Officer, will participate in a fireside chat on Wednesday, March 10, at 1:50 p.m. EST. A live webcast of the discussion will be accessible through the  Investor Relations section of the Company’s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Our primary customers are biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our
external link icon
Repligen Appoints Carrie Eglinton Manner to Board of Directors
WALTHAM, Mass., June 15, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced the appointment of healthcare industry executive Carrie Eglinton Manner to its Board of Directors. Ms. Eglinton Manner brings to the director role over 23 years of leadership experience across multiple disciplines. She currently serves as Senior Vice President, Advanced Diagnostics at Quest Diagnostics (NYSE:DGX), the world’s leading provider of diagnostic information services, which she joined in 2017. Prior to Quest, Ms. Eglinton Manner held various roles of increasing scope and responsibility over a period of 20 years at GE Healthcare (NYSE:GE). From 2009 through 2016, she served as President & CEO of four distinct GE Healthcare global businesses in the areas of diagnostic imaging, lab services and medical devices, ranging in size from approximately $150 million to $3 billion in revenue. “We are truly pleased to welcome Carrie as a director to our Board,” said Karen A. Dawes,
external link icon
Repligen Appoints Rohin Mhatre, Ph.D. to Board of Directors
WALTHAM, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced the appointment of life sciences industry executive Rohin Mhatre, Ph.D., to its Board of Directors. Dr. Mhatre brings to the director role over 25 years of relevant experience, which includes his current position as Senior Vice President, Product and Technology Development for Biogen Inc., a leading multinational biopharmaceutical company. Dr. Mhatre leads a cross-functional department responsible for product and process development, process analytics and small-scale manufacturing. Most recently, he has also led the Engineering and Manufacturing Science departments. Throughout his career, he has evaluated and implemented cutting-edge production platforms and process analytical tools for a diverse array of therapeutics, including monoclonal antibodies, gene therapies and oligonucleotides, as well as small molecules.

“We are delighted to welcome Dr. Mhatre to our board,” said
external link icon
Repligen to Present at Jefferies 2018 Global Healthcare Conference
WALTHAM, Mass., May 23, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a global bioprocessing company focused on the development and commercialization of highly innovative technologies to improve biopharmaceutical manufacturing processes, today announced that Jon K. Snodgres, Chief Financial Officer, will present at the Jefferies 2018 Global Healthcare Conference. The conference will take place on June 5-8 in New York City, and the Repligen presentation is scheduled for Wednesday, June 6 at 3:00 p.m. EDT. A live webcast of the presentation will be accessible through the Investor Relations section of Repligen’s website, and will be archived for a period of time following the live event.

About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a global bioprocessing company that develops and commercializes highly innovative products that deliver cost and process efficiencies to biological drug manufacturers worldwide. Our portfolio includes Protein